Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over Study of Sabatolimab in Myeloid Malignancies
2024-515281-14-00Phase 2Authorised
- Sponsor
- Novartis
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of sabatolimab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML), sponsored by Novartis. Primary endpoint: Frequency and severity of AEs and SAEs. Planned start Feb 2023; status: authorised.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2024-515281-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515281-14-00.